Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655264 | 1.00 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL7010951 | 0.87 | MMP9 (0.50) | ACACBACACA | |
| SCHEMBL30202565 | 0.86 | ACACB (0.50) | ACACBACACA | |
| SCHEMBL20791689 | 0.85 | L3MBTL1 (0.53) | — | |
| SCHEMBL13778592 | 0.85 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL20791688 | 0.85 | L3MBTL1 (0.53) | — | |
| SCHEMBL10315770 | 0.84 | L3MBTL1 (0.45) | — | |
| SCHEMBL6966307 | 0.83 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL15022611 | 0.83 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL5987917 | 0.82 | ACACB (0.54) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | claimed |
| CN-122036790-A | Chiral phosphine-acyclic phosphoramidite ligand, preparation method and application thereof | 中国科学院大连化学物理研究所 | 2026-05-15 | — | — | CN | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-107653233-B | improved aminotransferase, its coding gene and genetically engineered bacterium for expressing said enzyme | 泰州学院 | 2020-01-31 | — | — | CN | disclosed |
| CN-107108531-A | 4-oxo-3, 4-dihydro-1, 2, 3-benzotriazines as modulators of GPR139 | 武田药品工业株式会社 | 2017-08-29 | — | — | CN | disclosed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150315148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9051269-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140315949-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-6399787-B1 | TRANSITION METAL COMPLEX | PENN STATE RESEARCH FOUNDATION | 2002-06-04 | — | — | US | disclosed |
| EP-0812363-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINES | BAYER AG (DE) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999059721-A1 | CATALYTIC ASYMMETRIC HYDROGENATION, HYDROFORMYLATION, AND HYDROVINYLATION VIA TRANSITION METAL CATALYSTS WITH PHOSPHINES AND PHOSPHITES | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0812363-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINES | BAYER AG (DE) | 1997-12-17 | — | — | EP | disclosed |
| WO-1996027022-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | ACACB 4126/4885ACACA 4023/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | ACACB 4126/4885ACACA 4023/4885 |
| US-20150315148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | ACACB 610/4885ACACA 1171/4885 |
| US-20140315949-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | ACACB 610/4885ACACA 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.